Follow-On Biologics Guidance Delayed, Agency Tells BIO
This article was originally published in The Pink Sheet Daily
Executive Summary
Broad scope and broad "interest" in the topic mean it will take FDA longer than expected to complete work on the highly anticipated guidance, Acting Deputy Commissioner Woodcock says. The guidance will include an "inventory" of different ways protein products have been regulated by the agency.